MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Illumina Retained Earnings 2011-2026 | ILMN
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.24 B | -19 M | 5.48 B | 4.72 B | - | 4.07 B | 3.08 B | 1.49 B | 1.02 B | - | 561 M | 208 M | -68.7 M | -155 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.48 B | -1.24 B | 1.6 B |
Quarterly Retained Earnings Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -726 M | -876 M | - | -2.13 B | -145 M | 911 M | 1.14 B | 1.14 B | - | 5.1 B | 5.63 B | 4.72 B | 5.37 B | 5.06 B | 4.87 B | - | 4.47 B | 4.29 B | 4.24 B | 4.07 B | 4.07 B | 4.07 B | 4.07 B | 3.08 B | 3.06 B | 3.06 B | 3.06 B | 2.26 B | 2.26 B | 2.26 B | 2.26 B | 1.02 B | 1.36 B | 1.23 B | 1.11 B | - | 918 M | 800 M | 698 M | 561 M | 561 M | 561 M | 561 M | 208 M | 208 M | 208 M | 208 M | 82.5 M | 82.5 M | 82.5 M | 82.5 M | -155 M | -80.4 M | -101 M | -131 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.63 B | -2.13 B | 1.78 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 115.55 | 1.0 % | $ 35.1 B |  USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.67 | -2.34 % | $ 2.22 M | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.23 | 5.83 % | $ 1.13 B | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.46 | 3.25 % | $ 679 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.31 | 1.75 % | $ 493 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 169.8 | 1.23 % | $ 8.42 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 88.91 | 1.18 % | $ 11.1 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 84.33 | 1.82 % | $ 5.69 B | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.98 | -2.37 % | $ 8.76 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 410.54 | 4.35 % | $ 11.8 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.54 | 2.03 % | $ 2.07 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.14 | -0.47 % | $ 4.92 M | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.23 | -0.12 % | $ 386 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 102.17 | -3.92 % | $ 8.43 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 263.8 | -0.43 % | $ 21.9 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 121.03 | 6.58 % | $ 5.66 B | USA |
 |
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.29 | 4.8 % | $ 1.06 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.78 | -0.21 % | $ 443 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 203.75 | 1.3 % | $ 20.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 196.27 | -1.66 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
6.05 B | - | -0.91 % | $ 14.7 B | USA |
 |
Organovo Holdings
ONVO
|
-342 M | - | -2.3 % | $ 19.4 M | USA |
 |
Precipio
PRPO
|
-103 M | $ 28.0 | 3.57 % | $ 44.9 M | USA |
 |
Personalis
PSNL
|
-550 M | $ 6.1 | 3.39 % | $ 361 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 20.69 | 0.49 % | $ 223 M | China |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.56 | -0.64 % | $ 468 M | USA |